Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.69 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.69 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.56 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.56 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.56 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.55 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352420 | 1.00 | P2RX3 (0.69) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL532424 | 1.00 | P2RX3 (0.69) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL9189337 | 0.96 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL12352429 | 0.96 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL13169185 | 0.96 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL12243789 | 0.96 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL12222452 | 0.90 | P2RX3 (0.64) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL5794949 | 0.89 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL5983100 | 0.89 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1P2RX1 | |
| SCHEMBL532929 | 0.89 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7795238-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100152126-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20030225028-A1 | 2'-deoxy-beta-L-erythropentofuranonucleoside or a salt or prodrug thereof | GOSSELIN GILLES (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030220290-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B | CENTRE NATIONAL DA LA RESERCHE SCIENTIFIQUE | 2003-11-27 | — | — | US | disclosed |
| US-6596700-B2 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | IDENIX PHARMACEUTICALS INC. | 2003-07-22 | — | — | US | disclosed |
| US-6569837-B1 | Administering 2'-deoxy-beta-L-erythro-pentofuranonucleoside alone or with another anti-hepatitis B agent such as 3TC (beta-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane); use of beta-l-thymidine (telbivudine) | IDENIX PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| US-6566344-B1 | Administering beta-L-2'-deoxycytidine compound for therapy of hepatitis B virus infection | IDENIX PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-6444652-B1 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B | NOVIRIO PHARMACEUTICALS LIMITED (CY) | 2002-09-03 | — | — | US | disclosed |
| US-6395716-B1 | Antivirals such as telbivudine | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2002-05-28 | — | — | US | disclosed |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | NOVARTIS AG (CH) | 2002-03-21 | — | — | US | disclosed |
| EP-1104436-A2 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B VIRUS | Idenix (Cayman) Limited (KY) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | DCTD, DUT, DPYD | P2RX3 2900/4885P2RX4 3045/4885P2RX2 2568/4885 |
| US-20030225028-A1 | 2'-deoxy-beta-L-erythropentofuranonucleoside or a salt or prodrug thereof | ATIC, DUT, GART | P2RX3 1836/4885P2RX4 2236/4885P2RX2 1538/4885 |
| US-20100152126-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
| US-20030220290-A1 | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B | DUT, PNP, ATIC | P2RX3 1528/4885P2RX4 2004/4885P2RX2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.